UGCG and synucleinopathy: Following our evaluation of GCS inhibitors using GZ667161 to mediate disease pathology in GBA-related synucleinopathy mice (GbaD409V/WT), we sought to evaluate the efficacy of the clinical candidate GCS inhibitor compound, venglustat.